Overview
Tilda.bio provides patient-support services for clinical trial participation. It helps potential participants access and understand trials, coordinate tests around their schedules, and arrange transportation and other logistics to make trial participation smoother. The service is funded by pharmaceutical sponsors, who pay for participant management to improve trial completion rates and data reliability. Compared with others, Tilda.bio focuses directly on the participant experience and logistics to increase retention and data quality for sponsors. The company’s goal is to enhance patient care in clinical trials by delivering practical, schedule-friendly support that leads to higher trial completion and better data for drug development.
Work here?Claim your company
Simplify's take
What believers are saying
- October 2026: Tilda says deployment takes weeks, which shortens sales cycles for sponsors.
- Its AI Teammates reduce CRAs, coordinators, and manual TMF work, protecting sponsor margins.
- If current customers expand across more studies, Tilda can grow without proportional headcount.
What critics are saying
- 2026: One audit failure or data-integrity incident would damage trust with sponsors immediately.
- Competitors from Veeva, Medidata, and CROs can bundle similar workflow automation fast.
- Tilda’s value depends on regulated AI execution; one recurring error kills renewals and expansion.
What makes Tilda unique
- October 2026: Tilda Research sells AI Teammates executing ClinOps inside existing eClinical stacks.
- October 2026: Tilda claims 300+ studies, 10,000+ sites, and 45 countries.
- Tilda’s TMF product auto-files documents, runs QC, and closes work orders with traceability.
Help us improve and share your feedback! Did you find this helpful?